Rigel Announces Fourth Quarter and Year End 2006 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2006.
For the fourth quarter of 2006, Rigel reported a net loss of $15.5 million, or $0.62 per share, compared to a net loss of $8.9 million, or $0.36 per share, in the fourth quarter of 2005. Weighted average shares outstanding for the fourth quarters of 2006 and 2005 were 25.1 million and 24.5 million, respectively.
Rigel reported revenue from collaborations of $3.1 million in the fourth quarter of 2006, compared to $6.0 million in the fourth quarter of 2005. Revenue in the fourth quarter of 2005 included $2.5 million related to the upfront amortization for the Serono collaboration signed in October 2005.
Total operating expenses were $20.0 million in the fourth quarter of 2006, compared to operating expenses of $16.1 million in the fourth quarter of 2005. The increase in operating expenses was primarily due to stock-based compensation expense of $2.4 million in the fourth quarter of 2006, compared to stock-based compensation recovery of $2.2 million in the same period last year.
For the year ended December 31, 2006, Rigel had revenues of $33.5 million and a net loss of $37.6 million, or a loss per share of $1.51. This compares to revenues of $16.5 million and a net loss of $45.3 million, or a loss per share of $2.07 for the same period in 2005.
As of December 31, 2006, Rigel had cash, cash equivalents and available- for-sale securities of $104.5 million, compared to $115.0 at September 30, 2006 and $138.2 million at December 31, 2005. Net cash used in the fourth quarter of 2006 was $10.5 million.
'The steady progress of our clinical development programs, particularly in regard to our lead product candidate, R788, has expanded our efforts into additional indications, including immune thrombocytopenic purpura (ITP) and lymphoma,' said James M. Gower, chairman and chief executive officer of Rigel. 'In 2007, we anticipate being able to deliver Phase 2 data for R788 in the clinical areas of ITP and rheumatoid arthritis, while we continue to advance other product candidates in our growing portfolio.'
Recent Events:
* Initiated a Phase 2 study of R788 for the treatment of ITP (2007)
* Filed an investigational new drug (IND) application with the U.S. Food
and Drug Administration for R788 for the treatment of lymphoma (Fourth
Quarter of 2006)
* Selected R348, an orally-available, selective inhibitor of Janus Kinase
3 (JAK3) to enter preclinical studies (Fourth Quarter of 2006)
About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to file one new IND in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Contact: Ryan Maynard
Phone: (650) 624-1284
Email: invrel@rigel.com |
